Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

Contact Supplier

AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

DEVELOPMENTS

46 Drugs in Development

46 Drugs in Development

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 54 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
54 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

46DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1048007-93-7, Masitinib (mesylate), Masivet, Ab-1010 mesylate, Masitinib mesilate, Ab 1010 mesylate

Molecular Formula

C₂₉H₃₄N₆O₄S₂

Molecular Weight

594.8 g/mol

InChI Key

TXCWBWKVIZGWEQ-UHFFFAOYSA-N

FDA UNII

ZK89EG3A18

Masitinib Mesylate is the orally bioavailable mesylate salt of masatinib, a multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Masitinib selectively binds to and inhibits both the wild-type and mutated forms of the stem cell factor receptor (c-Kit; SCFR); platelet-derived growth factor receptor (PDGFR); fibroblast growth factor receptor 3 (FGFR3); and, to a lesser extent, focal adhesion kinase (FAK). As a consequence, tumor cell proliferation may be inhibited in cancer cell types that overexpress these receptor tyrosine kinases (RTKs).

1 2D Structure

Masitinib Mesylate

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide

2.1.2 InChI

InChI=1S/C28H30N6OS.CH4O3S/c1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34;1-5(2,3)4/h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32);1H3,(H,2,3,4)

2.1.3 InChI Key

TXCWBWKVIZGWEQ-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC(=CS4)C5=CN=CC=C5.CS(=O)(=O)O

2.2 Other Identifiers

2.2.1 UNII

ZK89EG3A18

2.3 Synonyms

2.3.1 MeSH Synonyms

1. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-(pyridin-3-yl)-1,3-thiazol-2-yl)amino)phenyl)benzamide

2. Ab 1010

3. Ab-1010

4. Ab1010

5. Kinavet

6. Kinavet Ca-1

7. Masatinib

8. Masican

9. Masitinib

10. Masitinib Mesilate

11. Masitinib Methanesulfonate

12. Masivet

13. Masiviera

2.3.2 Depositor-Supplied Synonyms

1. 1048007-93-7

2. Masitinib (mesylate)

3. Masivet

4. Ab-1010 Mesylate

5. Masitinib Mesilate

6. Ab 1010 Mesylate

7. Kinavet

8. Zk89eg3a18

9. Masican

10. Masiviera

11. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulfonate

12. 4-((4-methylpiperazin-1-yl)methyl)-n-(4-methyl-3-((4-pyridin-3-yl-1,3-thiazol-2-yl)amino)phenyl)benzamide Methanesulphonate

13. 4-(4-methyl-piperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl-thiazol-2-ylamino)-phenyl]-benzamide Methanesulfonate

14. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulfonate (1:1)

15. Benzamide, 4-((4-methyl-1-piperazinyl)methyl)-n-(4-methyl-3-((4-(3-pyridinyl)-2-thiazolyl)amino)phenyl)-, Methanesulphonate (1:1)

16. 4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide Mesylate

17. 928671-85-6

18. Methanesulfonic Acid;4-[(4-methylpiperazin-1-yl)methyl]-n-[4-methyl-3-[(4-pyridin-3-yl-1,3-thiazol-2-yl)amino]phenyl]benzamide

19. Unii-zk89eg3a18

20. Masitinibmesylate

21. Schembl1096348

22. Dtxsid70146747

23. Bcp30695

24. Ex-a3996

25. Masitinib Mesilate [who-dd]

26. Yrb00793

27. Hy-10209a

28. Cs-1593

29. Masitinib Mesylate [green Book]

30. Masitinib Methanesulfonate [mi]

31. Sb14845

32. Ac-30896

33. As-56731

34. Ft-0707180

35. C71194

36. Masitinib Mesylate [ema Epar Veterinary]

37. A927557

38. Q27295645

39. Ab1010 Mesylate;ab-1010 Mesylate;ab 1010 Mesylate

40. Masitinib Mesylate Salt; Masitinib Mesilate;ab 1010 Mesylate Pound>>ab1010 Mesylate Pound>>ab-1010 Mesylate

41. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate

42. N-(4-methyl-3-((4-(pyridin-3-yl)thiazol-2-yl)amino)phenyl)-4-((4-methylpiperazin-1-yl)methyl)benzamide Methanesulfonate;

2.4 Create Date

2008-11-17

3 Chemical and Physical Properties

Molecular Formula	C₂₉H₃₄N₆O₄S₂
Molecular Weight	594.8 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	7
Exact Mass	594.20829593 g/mol
Monoisotopic Mass	594.20829593 g/mol
Topological Polar Surface Area	164 Å²
Heavy Atom Count	41
Formal Charge	0
Complexity	788
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Treatment of amyotrophic lateral sclerosis.

Treatment of mastocytosis

Treatment of non resectable locally advanced or metastatic pancreatic cancer

Treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST)

Treatment of non-resectable dog mast-cell tumours (grade 2 or 3) with confirmed mutated c-KIT tyrosine-kinase receptor.

Treatment of mastocytosis

Treatment of gastro-intestinal stromal tumours

Treatment of amyotrophic lateral sclerosis

5 Pharmacology and Biochemistry

5.1 ATC Code

L01XE22

L01XE

QL01XE90

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

ABOUT THIS PAGE

Find Masitinib Mesylate manufacturers, exporters & distributors on PharmaCompass

Masitinib

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers

1 Listed Suppliers

DEVELOPMENTS

46 Drugs in Development

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow

54 NEWS #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

46DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

PATENTS & EXCLUSIVITIES

DIGITAL CONTENT

GLOBAL SALES INFORMATION

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

What are you looking for?